icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
Ribavirin Dose Modification in Treatment-naïve and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies
 
 
  Reported by Jules Levin
EASL 2012
 
M.S. Sulkowski1*, S. Roberts2, N.H. Afdhal3, P. Andreone4, M. Diago5, S. Pol6, F. Poordad7, S. Zeuzem8, L. Bengtsson9, D. Luo10, J. Witek10, N. Adda9
 
1. Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2. Alfred Hospital, Melbourne, VIC, Australia, 3. Beth Israel Deaconess Medical Center, Boston, MA, USA, 4. Universita di Bologna, Bologna, Italy, 5. Hospital General de Valencia, Valencia, Spain, 6. Université Paris Descartes, Paris, France, 7. Cedars-Sinai Medical Center, Los Angeles, CA, USA, 8. Johann Wolfgang Goethe University, Frankfurt/Main, Germany, 9. Vertex Pharmaceuticals Incorporated, Cambridge, MA, 10. Janssen Research and Development, Titusville, NJ, USA.

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

Patient Disposition According to Ribavirin Dose Reductions
 
Figure 1: A) Ribavirin Dose Reductions in Treatment-naïve Patients From ADVANCE and ILLUMINATE During the Overall Treatment Phase B) Ribavirin Dose Reductions in Previously Treated Patients from REALIZE During the Overall Treatment Phase

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif